SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021291
Filing Date
2023-05-11
Accepted
2023-05-11 16:22:02
Documents
61
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q antx-20230331.htm   iXBRL 10-Q 2446411
2 EX-31.1 antx-ex31_1.htm EX-31.1 20951
3 EX-31.2 antx-ex31_2.htm EX-31.2 21369
4 EX-32.1 antx-ex32_1.htm EX-32.1 10833
5 EX-32.2 antx-ex32_2.htm EX-32.2 10567
  Complete submission text file 0000950170-23-021291.txt   7898608

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT antx-20230331.xsd EX-101.SCH 54929
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT antx-20230331_lab.xml EX-101.LAB 433797
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT antx-20230331_cal.xml EX-101.CAL 39760
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT antx-20230331_pre.xml EX-101.PRE 330285
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT antx-20230331_def.xml EX-101.DEF 212519
55 EXTRACTED XBRL INSTANCE DOCUMENT antx-20230331_htm.xml XML 1188003
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41331 | Film No.: 23911395
SIC: 2834 Pharmaceutical Preparations